14 results about "Suppressed appetite" patented technology

A sublingual phentermine spray composition for daytime use comprises phentermine in a pharmaceutically-acceptable carrier and a sublingual phentermine spray composition for nighttime use comprises phentermine and a sleep aid in a pharmaceutically-acceptable carrier. Sublingual administration of sublingual phentermine spray compositions in accordance with the present disclosure provides an alternative to oral administration, avoiding such side effects as daytime drowsiness and intestinal disturbances. Nighttime use compositions comprising a sleep aid such as melatonin help manage the usual insomnia experienced when using phentermine. These compositions find use in suppressing appetite, for losing weight, and for maintaining a desired personal appearance.

The invention belongs to the technical field of biological medicines, and particularly relates to application of dronedarone hydrochloride in preparation of anti-obesity and anti-diabetes medicines. According to the invention, ob / ob mouse and db / db mouse models are used, and experiments find that dronedarone hydrochloride can significantly reduce the weight of obese and diabetic mice, inhibit appetite, reduce fat content and liver weight, improve pancreas islet function, reduce serum glucose level, and effectively alleviate obesity and diabetes diseases. The potential application of dronedarone hydrochloride in treatment of obesity and type II diabetes provides new possibility for clinical treatment, and dronedarone hydrochloride is expected to become a new medicine for treating obesity and type II diabetes.

Provided is use of leuconostoc mesenteroides and / or metabolites thereof in preparing a composition for reducing body fat, suppressing appetite, promoting the ketone body level or regulating fasting blood glucose, wherein the leuconostoc mesenteroides is leuconostoc mesenteroides subsp. mesenteroides with the preservation number of DSM34443.

Provided herein are methods of treating, preventing, or reducing one or more symptoms or conditions associated with metabolic dysfunction, such as obesity, in a subject in need thereof using a non-naturally occurring melanocortin analog. In some embodiments, the non-naturally occurring melanocortin analog is administered orally. In some embodiments, the method comprises suppressing appetite in a subject in need thereof using a non-naturally occurring melanocortin analog in accordance with the present technology.

The present invention relates to the field of treatment for body composition changes in weight management. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.

Provided herein are methods of treating, preventing, or reducing one or more symptoms or conditions associated with metabolic dysfunction, such as obesity, in a subject in need thereof using a non-naturally occurring melanocortin analog. In some embodiments, the non-naturally occurring melanocortin analog is administered orally. In some embodiments, the method comprises suppressing appetite in a subject in need thereof using a non-naturally occurring melanocortin analog in accordance with the present technology.

Disclosed herein are compounds and ligands, and compositions formed therewith, which modulate insulin secretion, suppress appetite, and reduce body mass by activating G-protein coupled receptors (GPCRs), such as ectopic olfactory receptors, and transient receptor potential (TRP) ion channels. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes and obesity.

The invention discloses a solution for promoting fat burning and inhibiting appetite and a preparation method thereof. Normal saline is treated through low-temperature plasma (CAP) to become activated normal saline; the activated normal saline contains a large amount of active oxygen and active nitrogen, and after the normal saline is injected into the body, the active ingredients of the normal saline can promote fat burning and inhibit appetite through various ways, so that the effects of reducing fat and losing weight are achieved. Compared with an existing weight-losing mode, the weight-losing composition is free of side effects, quite obvious in effect and short in period. The invention fills up the blank of research on fat burning promotion and appetite inhibition of the plasma activation liquid.

This invention provides a weight-loss formulation for subjects, wherein the active ingredient of the weight-loss formulation is carrageenan. This invention also provides the application of the active ingredient composed of carrageenan in the preparation of the weight-loss formulation for subjects. This invention creatively uses carrageenan alone as an active ingredient for weight loss, achieving very good weight-loss effects. At 24h, 48h, 72h, and 96h after injection, body weight decreased by 9.97% (P<0.05), 10.24% (P<0.05), 11.19% (P<0.01), and 13.21% (P<0.01), respectively, showing a gradually increasing trend, rapid onset, and significant effect. The weight-loss effect is superior to the latest oral weight-loss drug, the small-molecule GLP-1R agonist orforglipron. Furthermore, carrageenan, as an active ingredient, can also suppress appetite, reduce defecation, and increase urination.

The present invention relates to methods for incremental weight loss and to the field of treatment to improve body composition changes and physical function with weight reduction. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), GIP, glucagon, amylin, or by sodium-glucose transport protein 2 (SGLT-2) inhibitors.

The present invention relates to the field of treatment for body composition changes in weight management. In some embodiments, the present invention provides compositions and methods for mitigating the adverse effects of treatment by weight loss drugs that suppress appetite including incretin agonist or antagonist containing drugs such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or by sodium-glucose transport protein 2 (SGLT-2) inhibitors. In one embodiment, the present invention provides a composition of semaglutide and a selective androgen receptor modulator (SARM) compound of Formula IX.

The invention relates to a decoloring material for a lens surface coating film in vision, scenery or food is black and white in human eyes by filtering a specific spectrum so as to inhibit appetite, and the decoloring material is suitable for the field of fat reduction and sugar control. Different from traditional glasses, the color is directly converted into black and white through spectrum filtering, food temptation is reduced, and the brightness and definition of scenery are not changed. Meanwhile, by combining blue light resistance and ultraviolet protection functions, blue light damage to an electronic screen is reduced, ultraviolet rays are blocked, and the anti-blue-light protective film is suitable for long-term use of electronic equipment or use in a strong light environment. In addition, the anti-fog function is introduced, it is ensured that the lens is not fogged in the high-temperature and high-humidity environment, and the sight line is kept clear.

In an embodiment, the present disclosure pertains to an organ-specific wireless optogenetic device. In some embodiments, the device includes an electronic circuit, such that the electronic circuit is configured to harvest and convert radio frequency (RF) energy into optical energy and a tether having a μLED, where the μLED illuminates targeted regions in the organ. In an additional embodiment, the present disclosure pertains to a method of treating obesity. In general, the method includes implanting an organ-specific wireless optogenetic device into a subject, activating an RF-power system to produce RF energy, harvesting, by the organ-specific wireless optogenetic device, the RF energy, converting, by the organ-specific wireless optogenetic device, the RF energy into optical energy, illuminating, by the μLED, targeted regions in the stomach of the subject, and stimulating nerve endings to thereby suppress appetite in the subject.

The invention provides a stropharia rugoso-annulata double-target glycopeptide weight-reducing agent and application thereof, and belongs to the technical field of glycopeptides. The glycopeptide is composed of a polypeptide and a sugar chain, the amino acid sequence of the polypeptide is shown as SEQ ID NO.1, the sugar chain is N-acetyl glucosamine, and the N-acetyl glucosamine is connected to a first serine hydroxyl group of the polypeptide through an alpha-glucosidic bond in an O-connection glycosylation mode. The glycopeptide disclosed by the invention can be combined with the leptin, stabilize the four-spiral-beam conformation of the leptin, delay the degradation of the leptin, enhance the binding effect of the leptin and a leptin receptor and activate a melanocortin-4 receptor, and has potential multi-path weight-losing effects of inhibiting appetite and promoting energy consumption.